Retinitis Pigmentosa Clinical Trial
Official title:
Longitudinal Observation and Assessment of the Suprachoroidal Retinal Prostheses
Verified date | March 2023 |
Source | Center for Eye Research Australia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is a longitudinal observational study with participants who have been implanted with the suprachoroidal retinal prosthesis.
Status | Enrolling by invitation |
Enrollment | 7 |
Est. completion date | December 9, 2026 |
Est. primary completion date | December 9, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Willing to provide signed informed consent; - Implanted with a suprachoroidal retinal prosthesis; - Be available for the study visits; - Willing to comply with study assessments; - In good general health and mobile. Exclusion Criteria: - Medical condition that prohibits mobility; - Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study. |
Country | Name | City | State |
---|---|---|---|
Australia | Centre for Eye Research Australia | Melbourne E. | Victoria |
Lead Sponsor | Collaborator |
---|---|
Center for Eye Research Australia | Australian National University, Bionic Vision Technologies, Bionics Institute, Commonwealth Scientific and Industrial Research Organisation, Australia |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effectiveness of vision processing method in the laboratory. | Measure effectiveness of of the vision processing method via observational and quantitative data. | 5 years. | |
Primary | Effectiveness of vision processing method in the 'real world' featured environment. | Measure the effectiveness of the vision processing method via observational qualitative and quantitative data in participant 'real world' featured environment. | 5 years. | |
Secondary | Device stability and functionality. | Monitor device stability with routine ophthalmic imaging, impedance and threshold testing. | 5 years. | |
Secondary | Participant experience. | Document participant anecdotal experience with the VP method in 'real world' environments. | 5 years | |
Secondary | Participant interview. | Interview participants to capture participant experience with the ScRP, determine differences in functional outcomes and utilise this information to improve assessment of functional outcomes. | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01432847 -
Cell Collection to Study Eye Diseases
|
||
Completed |
NCT04983914 -
Retrospective NIS to Evaluate the Patient Benefit of TES
|
||
Recruiting |
NCT03845218 -
Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
|
||
Completed |
NCT00231010 -
Molecular Genetics of Retinal Degenerations
|
||
Active, not recruiting |
NCT04611503 -
PDE6A Gene Therapy for Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
Completed |
NCT02909985 -
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
|
N/A | |
Recruiting |
NCT01914913 -
Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
Completed |
NCT01949623 -
Biomarkers In Retinitis Pigmentosa (BIRP)
|
N/A | |
Completed |
NCT01835002 -
Transcorneal Electrical Stimulation - Multicenter Safety Study
|
N/A | |
Completed |
NCT00407602 -
Argus® II Retinal Stimulation System Feasibility Protocol
|
N/A | |
Completed |
NCT00515814 -
Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors
|
N/A | |
Completed |
NCT00100230 -
DHA and X-Linked Retinitis Pigmentosa
|
Phase 2 | |
Active, not recruiting |
NCT00378742 -
Repository for Inherited Eye Diseases
|
||
Terminated |
NCT05085964 -
An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
|
Phase 2 | |
Recruiting |
NCT05805007 -
Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa
|
Early Phase 1 | |
Recruiting |
NCT05909488 -
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
|
Phase 2/Phase 3 | |
Recruiting |
NCT06291935 -
Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene
|
Phase 1 | |
Recruiting |
NCT03078309 -
The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients
|
Early Phase 1 | |
Completed |
NCT04238858 -
Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa
|
N/A | |
Active, not recruiting |
NCT01680510 -
The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil
|
Phase 1/Phase 2 |